MAT2A and neoplasm: The authors’ study using the MAT2A inhibitor, FIDAS-5, found that it greatly reduced the levels of SAM and SAH in the tumor-initiating cells, and lowered the levels of histone methylation, which resulted in the tumor clonogenic and tumorigenic abilities of the initiating cells were drastically reduced (35).